User:LovingerJ/sandbox

{{db-spam|help=off} {{unreferenced|date=January 2016}

Fina BioSolutions LLC (FinaBio) is a privately held biotechnology company located in Rockville, Maryland. The company specializes in the field of bioconjugation, especially protein-polysaccharide conjugate vaccines. FinaBio is a consulting laboratory, providing both consulting and laboratory services. The services offered by the agency company are designed to aid biotech help researchers and companies working onto develop conjugate vaccines and other pre-clinical applications.

FinaBio Solutions has one subsidiary, FinaBio Reagents, which sells vaccine-related products, immunoreagents and polymer products.

Andrew Lees, FinaBio’s founder, is the developer of CDAP chemistry for conjugate vaccines (Lees, A., B.L. Nelson, and J.J. Mond. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.  Vaccine  14:190, 1995; Shafer, D.E., B. Toll, R.F. Schuman, B.L. Nelson, J.J. Mond and A. Lees. Activation of soluble polysaccharides with CDAP for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine.  18:1273, 2000). CDAP chemistry is currently used in GlaxoSmithKline’s conjugate vaccines for Streptococcus pneumoniae (Synflorix) and for Neisseria meningitidis (Nimenrix, Menhibrix, Menitorix).

History
FinaBio Solutions was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers make affordable conjugate vaccines. The company has expanded to offer a variety of bioconjugation and protein products and services. FinaBio currently has about 5000 sq feet of laboratory and office space. In 2015 FinaBio Solutions became the first and only company to produce and market the carrier protein CRM197 in E. coli. The product is marketed under the tradename EcoCRMTM, for Eeconomical CRM197 from E. coli.

FinaBio Reagents
FinaBio Reagents sells products relating to vaccines and infectious disease reagents, such as proteins, polysaccharides and antibodies. The division also sells immunoreagents and a collection of functionalized dextrans.